Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib Plus Standard Chemotherapy in Newly Diagnosed FLT3 Wild-type AML
NCT04107727Phase 2Completed
- Sponsor
- Fundación PETHEMA
- Start
- Sep 2019
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Quizartinib Arm with Placebo Arm (2 arms). Primary endpoint: Event-Free Survival at 5 years. Started Sep 2019; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04107727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04107727.